Abstract
We expanded GWAS discovery for type 2 diabetes (T2D) by combining data from 898,130 European-descent individuals (9% cases), after imputation to high-density reference panels. With these data, we (i) extend the inventory of T2D-risk variants (243 loci, 135 newly implicated in T2D predisposition, comprising 403 distinct association signals); (ii) enrich discovery of lower-frequency risk alleles (80 index variants with minor allele frequency <5%, 14 with estimated allelic odds ratio >2); (iii) substantially improve fine-mapping of causal variants (at 51 signals, one variant accounted for >80% posterior probability of association (PPA)); (iv) extend fine-mapping through integration of tissue-specific epigenomic information (islet regulatory annotations extend the number of variants with PPA >80% to 73); (v) highlight validated therapeutic targets (18 genes with associations attributable to coding variants); and (vi) demonstrate enhanced potential for clinical translation (genome-wide chip heritability explains 18% of T2D risk; individuals in the extremes of a T2D polygenic risk score differ more than ninefold in prevalence).
Original language | English |
---|---|
Pages (from-to) | 1505-1513 |
Number of pages | 9 |
Journal | Nature Genetics |
Volume | 50 |
Issue number | 11 |
Early online date | 8 Oct 2018 |
DOIs | |
Publication status | Published - 1 Nov 2018 |
Keywords
- Body Mass Index
- Case-Control Studies
- Chromosome Mapping/methods
- Diabetes Mellitus, Type 2/epidemiology
- Epigenesis, Genetic
- European Continental Ancestry Group/genetics
- Female
- Gene Frequency
- Genetic Loci/genetics
- Genetic Predisposition to Disease
- Genome, Human/genetics
- Genome-Wide Association Study
- High-Throughput Screening Assays/methods
- Humans
- Islets of Langerhans/metabolism
- Linkage Disequilibrium
- Male
- Meta-Analysis as Topic
- Polymorphism, Single Nucleotide
- Sex Factors